Thrombolytic TherapyStreptokinaseTissue Plasminogen ActivatorFibrinolytic AgentsMyocardial InfarctionThrombosisPlasminogen ActivatorsAnistreplasePulmonary EmbolismUrokinase-Type Plasminogen ActivatorStrokeHeparinTreatment OutcomeBrain IschemiaCoronary ThrombosisTime FactorsCerebral HemorrhageMyocardial ReperfusionEmbolectomyCarotid Artery ThrombosisThrombectomyAcute DiseaseVenous ThrombosisFibrinolysisCoronary Care UnitsHemorrhageFibrinElectrocardiographyAnticoagulantsAngioplasty, Balloon, CoronaryHeart Rupture, Post-InfarctionIntracranial ThrombosisCoronary AngiographyIntracranial Embolism and ThrombosisIntracranial HemorrhagesProspective StudiesFibrinolysinTomography, X-Ray ComputedInfusions, IntravenousRecurrenceBlood CoagulationIntracranial EmbolismVascular PatencyRecombinant ProteinsHirudin TherapyInjections, IntravenousFibrinopeptide AEmergency Medical ServicesInfusions, Intra-ArterialHeart DiseasesFibrinogenEmergenciesCerebral InfarctionRetrospective StudiesInjections, Intra-ArterialEmergency TreatmentCreatine KinaseCerebral AngiographyThrombophlebitisFollow-Up StudiesEmbolismEmergency Medical TechniciansRadionuclide VentriculographyAspirinReperfusionHospital MortalityAngiographyPlatelet AggregationCatheterization, PeripheralThromboembolismBlood PlateletsHemostasisFibrin Fibrinogen Degradation ProductsPatient SelectionHeart RuptureEye HemorrhagePredictive Value of TestsRisk FactorsArterial Occlusive DiseasesIliac VeinPlatelet Aggregation InhibitorsNewfoundland and LabradorRandomized Controlled Trials as TopicCerebrovascular DisordersSurvival AnalysisInfarction, Middle Cerebral ArteryStreptodornase and StreptokinaseDrug Therapy, CombinationCardiac CatheterizationPrognosisEcchymosisVena Cava, InferiorVena Cava FiltersPlasminogenHirudinsShock, CardiogenicHospitals, CommunityCatheterizationVentricular Septal RuptureSurvival Rate